Robert W. Baird reiterated their buy rating on shares of Agilent Technologies (NYSE:A) in a report published on Thursday morning. They currently have a $76.00 price target on the medical research company’s stock.
A number of other research firms have also weighed in on A. Goldman Sachs Group reaffirmed a neutral rating and set a $68.00 target price on shares of Agilent Technologies in a report on Tuesday, September 26th. Cowen reaffirmed a hold rating and set a $65.00 target price on shares of Agilent Technologies in a report on Thursday, September 28th. Evercore ISI assumed coverage on shares of Agilent Technologies in a report on Wednesday, January 3rd. They set an outperform rating and a $75.00 target price on the stock. Barclays reaffirmed a buy rating and set a $74.00 target price on shares of Agilent Technologies in a report on Monday, January 8th. Finally, Zacks Investment Research raised shares of Agilent Technologies from a hold rating to a buy rating and set a $76.00 target price on the stock in a report on Tuesday, October 31st. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $69.25.
Shares of Agilent Technologies (NYSE:A) opened at $73.07 on Thursday. Agilent Technologies has a 12-month low of $47.05 and a 12-month high of $73.21. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85. The stock has a market cap of $23,602.93, a P/E ratio of 30.83, a PEG ratio of 2.21 and a beta of 1.28.
Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.95%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the firm posted $0.59 earnings per share. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. sell-side analysts expect that Agilent Technologies will post 2.58 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 2nd will be issued a $0.149 dividend. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Friday, December 29th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.82%. Agilent Technologies’s dividend payout ratio is presently 28.57%.
In other news, CEO Michael R. Mcmullen sold 21,850 shares of the stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $72.50, for a total value of $1,584,125.00. Following the transaction, the chief executive officer now owns 324,687 shares of the company’s stock, valued at approximately $23,539,807.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael R. Mcmullen sold 22,481 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $68.77, for a total transaction of $1,546,018.37. Following the completion of the transaction, the chief executive officer now directly owns 336,637 shares in the company, valued at approximately $23,150,526.49. The disclosure for this sale can be found here. Insiders sold a total of 198,141 shares of company stock worth $13,830,045 in the last three months.
Large investors have recently modified their holdings of the company. Dupont Capital Management Corp purchased a new stake in shares of Agilent Technologies in the 3rd quarter valued at $101,000. Balentine LLC boosted its stake in shares of Agilent Technologies by 2.9% in the 2nd quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after purchasing an additional 50 shares in the last quarter. Sun Life Financial INC boosted its stake in shares of Agilent Technologies by 26,144.4% in the 2nd quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after purchasing an additional 2,353 shares in the last quarter. MML Investors Services LLC purchased a new stake in shares of Agilent Technologies in the 2nd quarter valued at $209,000. Finally, Prudential PLC purchased a new stake in shares of Agilent Technologies in the 2nd quarter valued at $211,000.
ILLEGAL ACTIVITY WARNING: “Agilent Technologies (A) Earns Buy Rating from Robert W. Baird” was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.truebluetribune.com/2018/01/21/agilent-technologies-a-earns-buy-rating-from-robert-w-baird.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.